AbbVie (ABBV) Stock Forecast & Price Target

Q: What analysts cover AbbVie?

AbbVie has been rated by research analysts at Argus , Bank of America , Barclays , BNP Paribas Exane , Canaccord Genuity Group , Cantor Fitzgerald , Erste Group Bank , Guggenheim , HSBC , JPMorgan Chase & Co. , Leerink Partners , Morgan Stanley , Oppenheimer , Piper Sandler , Rothschild & Co Redburn , Royal Bank Of Canada , Scotiabank , UBS Group , Weiss Ratings , Wells Fargo & Company , and Wolfe Research in the past 90 days.

$285.32 +1.92 (+0.68%)

Closing price 10/16/2026 03:59 PM Eastern

Extended Trading

$285.72 +0.40 (+0.14%)

As of 10/16/2026 07:57 PM Eastern

Compare

AbbVie - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 30 Analyst Ratings

Sell
0

Hold
6

Buy
24

Based on 30 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 6 have given a hold rating, 23 have given a buy rating, and 1 has given a strong buy rating for ABBV.

Consensus Price Target

$277.18
-2.85% Downside

According to the 30 analysts' twelve-month price targets for AbbVie, the average price target is $277.18. The highest price target for ABBV is $320.00, while the lowest price target for ABBV is $225.00. The average price target represents a forecasted downside of -2.85% from the current price of $285.32.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABBV Analyst Ratings Over Time

Type	Current Forecast 10/18/25 to 10/18/26	1 Month Ago 9/18/25 to 9/18/26	3 Months Ago 7/20/25 to 7/20/26	1 Year Ago 10/18/24 to 10/18/25
Strong Buy	1 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	23 Buy rating(s)	23 Buy rating(s)	18 Buy rating(s)	16 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$277.18	$272.66	$265.58	$235.48
Forecasted Upside	-2.85% Downside	3.32% Upside	4.82% Upside	2.53% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Healthcare Companies	Broader Market
Consensus Rating Score	2.83	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	-2.85% Downside	1,213.76% Upside	18.02% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/13/2026	Royal Bank Of Canada 2 of 5 stars	Trung Huynh Not Rated	Reiterated Rating	Outperform	$280.00	+0.58%
10/9/2026	Guggenheim 5 of 5 stars	Vamil Divan 4 of 5 stars	Reiterated Rating	Buy	$288.00	+4.85%
10/8/2026	Weiss Ratings 3 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Chris Schott Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$285.00 ➝ $300.00	+10.21%
10/8/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Carter Gould Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$285.00 ➝ $290.00	+6.87%
10/7/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Terence Flynn Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$296.00 ➝ $310.00	+14.10%
10/6/2026	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	Louise Chen Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$280.00 ➝ $320.00	+21.56%
10/6/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Yee Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$260.00 ➝ $275.00	+4.47%
9/10/2026	HSBC Subscribe to MarketBeat All Access to unlock brokerage rankings	Rajesh Kumar Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$300.00 ➝ $315.00	+25.48%
9/8/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Geoff Meacham Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy
Why major institutions are piling into this digital asset now (Ad) BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. Get the name, the ticker, and exactly how to buy it
8/20/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	David Amsellem Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$298.00 ➝ $303.00	+14.07%
8/17/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Mohit Bansal Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$295.00 ➝ $300.00	+20.38%
8/13/2026	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Alexandria Hammond Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Peer Perform ➝ Outperform	$235.00 ➝ $300.00	+20.42%
8/11/2026	BNP Paribas Exane Subscribe to MarketBeat All Access to unlock brokerage rankings	Navann Ty Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$218.00 ➝ $247.00	-1.15%
8/5/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Outperform	$245.00 ➝ $279.00	+4.74%
8/5/2026	Erste Group Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold ➝ Buy
8/4/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Buy	$284.00 ➝ $285.00	+6.99%
8/4/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target		$250.00 ➝ $270.00	+1.36%
8/3/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Gary Nachman Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$282.00 ➝ $290.00	+15.39%
8/3/2026	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Neutral	$244.00 ➝ $258.00	-3.15%
7/29/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Emily Field Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$275.00 ➝ $300.00	+13.86%
7/15/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Geoff Meacham Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$230.00 ➝ $260.00	+6.23%
7/13/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Evan David Seigerman Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$258.00 ➝ $300.00	+20.97%
6/23/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Market Perform	$203.00 ➝ $225.00	-4.00%
5/15/2026	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target	Outperform	$236.00 ➝ $235.00	+10.71%
5/5/2026	Daiwa Securities Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Outperform	$244.00 ➝ $237.00	-11.09%
4/30/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Neutral	$240.00 ➝ $244.00	-8.46%
4/30/2026	DZ Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold ➝ Strong-Buy
3/9/2026	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform
1/20/2026	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Luisa Hector Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target	Buy	$270.00 ➝ $275.00	+28.28%
11/3/2025	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Gary Nachman Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target	Outperform	$250.00 ➝ $256.00	+17.36%
10/3/2025	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Buy	$250.00 ➝ $280.00	+5.12%
9/15/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Hold	$173.00 ➝ $204.00	-23.41%
2/3/2025	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Srikripa Devarakonda Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$211.00 ➝ $217.00	+14.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:13 AM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 17, 2026. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie recently reported positive Phase 3 trial results for epcoritamab plus R-CHOP, which significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening the company's oncology pipeline and long-term growth potential.
The stock is trading at $285.32, a level that reflects strong year-to-date performance of over 23% and a forward price-to-earnings ratio of approximately 16.4, which analysts consider attractively valued for a large-cap pharmaceutical company compared to its trailing multiple.
AbbVie maintains a durable dividend profile with a current yield of 2.44%, and its top two drugs generate sufficient revenue to cover the payout, positioning it as a resilient Dividend King that can withstand various interest rate cycles.
Investors are benefiting from sector rotation as capital shifts toward defensive pharmaceutical companies amid weakening technology stocks, pushing AbbVie and other major drugmakers close to record highs and providing a safer bet in the current market environment.
Analyst sentiment remains favorable with a consensus rating of Moderate Buy, supported by recent price target increases from firms like Morgan Stanley and BMO Capital Markets, indicating confidence in the company's ability to offset declining Humira revenue with fast-growing newer medicines.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

The primary risk remains the transition away from established blockbusters, as AbbVie must prove that newer medicines can sustain earnings while mature products face increased competition, creating uncertainty about future revenue stability.
The company's trailing price-to-earnings ratio is elevated at 80.60, which may appear expensive to value-focused investors despite the more reasonable forward multiple, raising concerns about the current valuation relative to reported earnings.
AbbVie has a high payout ratio of 195.48%, meaning the dividend is not fully covered by current earnings, which could pose a risk to the sustainability of the income stream if earnings growth does not accelerate to match the payout.
Recent insider activity includes significant share sales by executives, such as EVP Nicholas Donoghoe selling 32,710 shares in August 2026, which may signal a lack of confidence in the stock's short-term upside from those closest to the company's operations.
Some institutional investors, including Cardinal Capital Management Inc. and Banque Pictet & Cie SA, reduced their holdings in the third quarter, suggesting that certain large funds are taking profits or reallocating capital away from the stock despite its recent rally.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $277.18, with a high forecast of $320.00 and a low forecast of $225.00.

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 6 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted downside of -2.85% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 4 upgrades by analysts.

AbbVie has been rated by research analysts at Argus, Bank of America, Barclays, BNP Paribas Exane, Canaccord Genuity Group, Cantor Fitzgerald, Erste Group Bank, Guggenheim, HSBC, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Oppenheimer, Piper Sandler, Rothschild & Co Redburn, Royal Bank Of Canada, Scotiabank, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like AbbVie more than other "healthcare" companies. The consensus rating for AbbVie is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AbbVie Recommendations

MarketBeat monitors more than a dozen sources for AbbVie analyst ratings, with the most recent rating issued on 10/13/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Stock Forecast & Price Target